Saturday, June 23, 2012

EW1 - EMPAG Workshop

EW1 Parents & Children in Families with Huntington's Disease
 L. B. Van der Meer¹, A. Blom²;
 ¹Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center, Amsterdam, Netherlands.

Opening: joint with ESHG Welcome addresses

EPL1 - EMPAG Plenary Session: Decision making and outcome in genetic counselling

EPL1.1 Priority setting in genetic testing: a pilot discrete choice experiment
F. Severin¹, J. Schmidtke², A. Mühlbacher³, W. Rogowski¹;
¹Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, ²Hannover Medical School, Institute for Human Genetics, Hanover, Germany, ³Hochschule Neubrandenburg, University of Applied Science, Neubrandenburg, Germany.

EPL1.2 First Trimester Screening, it's not a routine test An education module for General Practitioners to help women to make an informed choice
K. K. Barlow-Stewart^1,2, K. Dunlop²;
¹University of Sydney, Sydney, Australia, ²Centre for Genetics Education, Sydney, Australia.

EPL1.3 What do pregnant women and their partner know about Down Syndrome when they decide to undergo prenatal diagnosis?
C. Ingvoldstad¹, P. Lindgren², G. Annerén³, E. Ternby², O. Axelsson⁴;
¹Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden, ²Department of women´s and children´s health, Uppsala University, Uppsala, Sweden, ³Department of genetics and pathology, Uppsala University, Uppsala, Sweden, ⁴Department of women`s and children´s health, Uppsala University, Uppsala, Sweden.

EPL1.4 How do women make decisions about genetic carrier screening for fragile X syndrome? A qualitative study
A. G. Ames^1,2, A. D. Archibald¹, R. Duncan¹, J. Emery³, S. A. Metcalfe^1,2;
¹Murdoch Childrens Research Institute, Melbourne, Australia, ²University of Melbourne, Parkville, Australia, ³The University of Western Australia, Crawley, Australia.

EPL1.5 Development and validation of a short family history screening tool for chronic disease prevention in primary care
F. M. Walter^1,2, T. A. Prevost^1,3, L. Birt¹, N. Grehan¹, K. Restarick¹, H. C. Morris¹, P. Rose⁴, S. Downing⁵, S. Sutton¹, J. D. Emery^2,1;
¹University of Cambridge, Cambridge, United Kingdom, ²University of Western Australia, Perth, Australia, ³King's College London, London, United Kingdom, ⁴Oxford University, Oxford, United Kingdom, ⁵Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

EPL1.6 Measuring patient benefits from interventions in clinical genetics and genetic counselling services: Are we finally able to do this?
M. McAllister¹, A. M. Wood², G. Dunn², K. Payne², L. Davies², D. Donnai³, R. MacLeod², C. Todd²;
¹Cardiff University, Cardiff, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³St Mary's Hospital, Manchester, United Kingdom.

EPL2 - EMPAG Plenary Session: Risk communication and predictive tesing in Europe

EPL2.1 Breast cancer risk communication by health care providers' in 4 European countries
C. Julian-Reynier^1,2,3, A. Bouhnik^1,2, G. Evans⁴, H. Harris⁵, C. van Asperen⁶, A. Tibben^7,8, I. Nippert⁹;
¹INSERM, UMR912 "Health Economy, Social Sciences & Medical Information Processing" (SESSTIM), Marseilles, France, ²Aix-Marseille Université, UMR-S912, Marseille, France, ³Institut Paoli-Calmettes, Marseille, France, ⁴Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Central Manchester Foundation Trust, St Mary's Hospital, Manchester, United Kingdom, ⁵GenEd Coordinating Centre, University of Manchester, Manchester, United Kingdom, ⁶Center for Human and Clinical Genetics, Department of Clinical Genetics, Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁷Centre of Human and Clinical Genetics, Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁸Department of Clinical Genetics, Erasmus MC, Rotterdam, Netherlands, ⁹Women's Health Research, Münster Medical School, Münster, Germany.

EPL2.2 International variation in physicians' attitudes towards prophylactic mastectomy - comparison between the UK, France, Germany, and the Netherlands
M. den Heijer¹, C. J. van Asperen², H. Harris³, I. Nippert⁴, C. Julian-Reynier⁵, G. Evans⁶, A. Tibben²;
¹Department of Clinical Genetics, Erasmus MC, Rotterdam, Netherlands, ²Department of Clinical Genetics, Leiden University Medical Centre, Leiden, Netherlands, ³GenEd Coordinating Centre, University of Manchester, Manchester, United Kingdom, ⁴Women's Health Research, Munster Medical School, Munster, Germany, ⁵U912, INSERM, IRD, Institut Paoli-Calmettes, Aix-Marseille Universite, Marseille, France, ⁶Medical Genetics Research Group and Regional Genetics Services, St. Mary's Hospital, Manchester, United Kingdom.

EPL2.3 “Life at risk”: Negotiating identities on healthy carriers of a genetic alteration predisposing to cancer.
E. Sumalla¹, V. Castejon¹, C. Ochoa², Y. Valverde¹, A. Solanes³, G. Capella¹, I. Blanco^1,4;
¹Genetic Counseling Unit. Hereditary Cancer Program., L'Hospitalet, Spain, ²Psycho-Oncology Unit, L'Hospitalet, Spain, ³Genetic Counseling Unit. Hereditary Cancer Program., Badalona, Spain, ⁴Genetic Counseling Unit, Hereditary Cancer Program, Badalona, Spain.

EPL2.4 Women's experiences of familial ovarian cancer screening: A qualitative study
K. J. Lifford¹, A. Clements², L. Fraser³, D. Lancastle⁴, K. Brain¹;
¹Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, United Kingdom, ²Department of Primary Health Care Sciences, University of Oxford, Oxford, United Kingdom, ³Gynaecological Oncology, University College London Institute for Women's Health, London, United Kingdom, ⁴Department of Humanities and Social Sciences, University of Glamorgan, Pontypridd, United Kingdom.

EPL2.5 What counts as successful in genetic counselling for presymptomatic testing in late onset disorders? The consultands' perspective.
L. Guimarães¹, J. Sequeiros^2,1, H. Skirton³, M. Paneque Herrera^2,1;
¹ICBAS-Universidade do Porto, Porto, Portugal, ²CGPP-IBMC, Porto, Portugal, ³School of Nursing and Midwifery, University of Plymouth, Plymouth, United Kingdom.

EPL2.6 Impact of predictive genetic testing for Huntington's disease (HD), Familial Cardiomyopathy (FCM) and Hereditary Breast and Ovarian Cancer (HBOC) in young people
R. M. MacLeod¹, A. Beach², S. Henriques², J. Knopp², K. Nelson², L. Kerzin-Storrar¹;
¹Genetic Medicine, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²University of Manchester, Manchester, United Kingdom.

20:00 - 21:30

Sunday, June 24, 2012

Educational Session ES4 - Applying family dynamics/therapy in genetic counselling (joint Educational Session with ESHG)

ES4.1 The Family's Experience of a Genetic Disorder, Suzan McDaniel, USA

ES4.2 Using systemic ideas in Genetic Counsellors' group supervision, Tom O'Neill, UK

Poster Viewing with Authors (odd poster numbers)

Lunch, Free Poster Viewing, Exhibition

EPL3 - EMPAG Plenary Session: Reproductive issues and newborn screening

EPL3.1 The impact of NIPD on clinical practice: what do prenatal care providers need to know?
M. Bishop, J. Haydon, D. Latham, J. Tennant, P. Farndon;
NHS National Genetics Education and Development Centre, Birmingham, United Kingdom.

EPL3.2 Non-invasive prenatal diagnosis for fetal sex determination - benefits and disadvantages from the service users' perspective
C. Lewis¹, M. Hill², H. Skirton³, L. Chitty^4,2;
¹Genetic Alliance UK, London, United Kingdom, ²Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Faculty of Health, University of Plymouth, Plymouth, United Kingdom, ⁴Clinical and Molecular Genetics, UCL Institute of Child Health,, London, United Kingdom.

EPL3.3 Using discrete choice experiments to explore stakeholder preferences for non-invasive prenatal diagnosis compared to current invasive testing
M. Hill^1,2, F. Forya², J. Fisher³, S. Morris^4,5, L. Chitty^1,2;
¹Clinical and Molecular Genetics, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³Antenatal Results and Choices, London, United Kingdom, ⁴UCLH/UCL Comprehensive Biomedical Research Centre, London, United Kingdom, ⁵Research Department of Epidemiology and Public Health, University College London, London, United Kingdom.

EPL3.4 Ethical issues in the use of pronuclear and maternal spindle transfer to prevent mitochondrial disorders
T. Clancy;
Genetic Medicine, St Mary's Hospital, Manchester, United Kingdom.

EPL3.5 The impact of carrier results generated by newborn screening on the family
F. Ulph¹, T. Cullinan², N. Qureshi³, J. Kai³;
¹University of Manchester, Manchester, United Kingdom, ²East Staffordshire Clinical Commissioning Group, Burton upon Trent, United Kingdom, ³University of Nottingham, Nottingham, United Kingdom.

EPL3.6 Divergent views on newborn and infant genetic screening: perspectives of parents of healthy children and relatives of children with genetic conditions causing developmental delay
S. A. Metcalfe¹, A. D. Archibald^2,3, A. Atkinson¹, C. Hickerton², S. Lawton¹, B. McClaren², S. Wong¹;
¹Murdoch Childrens Research Institute and Dept Paediatrics, University of Melbourne, Parkville, Vic, Australia, ²Murdoch Childrens Research Institute, Parkville, Vic, Australia, ³Genetic Health Services Victoria, Parkville, Vic, Australia.

EW2 - EMPAG Workshop

EW2 Methodological guidelines for empirical validation of genetic counselling interventions
 J. C. Rocha;
 UnIPSa, ISCS-N, Gandra, Portugal.

Concurrent Symposium S08. 25 Years Psychosocial research in Clinical Genetics: Making up the balance (joint Sympopsium with ESHG)

S08.1 Past, present and future of psychological research in genetics: a personal view and a focus on the  impact of predictive testing, Gerry Evers-Kiebooms, Belgium

S08.2 Translation of psychosocial research findings into an evidence base for genetic counselling practice and training , lauren Kerzin-Storrar, United Kingdom

S08.3 Psychosocial issues in cancer genetics, Eveline Bleiker, The Netherlands

Monday, June 25, 2012

EPL4- EMPAG Plenary Session: Cancer genetic counselling

EPL4.1 Evaluation of the efficacy of two models of delivering information about treatment-focused genetic testing among young women newly diagnosed with breast cancer>
B. Rahman^1,2, B. Meiser^1,2, K. Watts^1,2, M. Gleeson^3,2, C. Saunders⁴, G. Mitchell⁵, K. Barlow-Stewart⁶, J. Kirk⁷, K. Tucker²;
¹Psychosocial Research Group, Sydney, Australia, ²Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia, ³Hunter Genetics, NSW, Australia, ⁴Department of Surgery, University of Western Australia, WA, Australia, ⁵Peter MacCallum Cancer Centre, VIC, Australia, ⁶Centre for Genetics Education, Sydney, Australia, ⁷Westmead Institute for Cancer Research, Sydney, Australia.

EPL4.2 Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm
K. E. Brain¹, K. J. Lifford¹, L. Fraser², A. N. Rosenthal^2,3, M. T. Rogers⁴, D. Lancastle⁵, C. Phelps⁶, E. K. Watson⁷, A. Clements⁸, R. Iredale⁴, I. Jacobs⁹, U. Menon²;
¹Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, United Kingdom, ²Gynaecological Oncology, University College London Institute for Women's Health, London, United Kingdom, ³Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom, ⁴School of Medicine, Cardiff University, Cardiff, United Kingdom, ⁵Department of Humanities and Social Sciences, University of Glamorgan, Pontypridd, United Kingdom, ⁶School of Psychology & Counselling, Swansea Metropolitan University, Swansea, United Kingdom, ⁷School of Health and Social Care, Oxford Brookes University, Oxford, United Kingdom, ⁸Department of Primary Health Care Sciences, University of Oxford, Oxford, United Kingdom, ⁹Faculty of Medical and Health Sciences, University of Manchester, Manchester, United Kingdom.

EPL4.3 Are illness perceptions a useful predictor of emotional distress over time in individuals undergoing cancer genetic risk assessment?
C. Phelps¹, P. Bennett², A. Murray³, K. Brain⁴;
¹Swansea Metropolitan University, Swansea, United Kingdom, ²Swansea University, Swansea, United Kingdom, ³Cancer Genetics Service for Wales, Cardiff, United Kingdom, ⁴Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom.

EPL4.4 The underestimated impact of prophylactic mastectomy
J. P. Gopie¹, R. Timman², M. T. Hilhorst², M. A. M. Mureau², A. Tibben^1,2;
¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands.

EPL4.5 The impact of risk-reducing hysterectomy and/or oophorectomy in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome
R. Moldovan^1,2, S. Keating^1,3, T. Clancy¹;
¹Genetic Medicine, University of Manchester, Manchester, United Kingdom, ²Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, Cluj-Napoca, Romania, ³Genetic Health Service, Auckland, New Zealand.

EPL4.6 The use of an electronic genealogy database in cancer genetic counseling in Iceland
V. Stefansdottir¹, O. T. Johannsson², H. Skirton³, L. Tryggvadottir⁴, H. Tulinius⁵, C. Chapman⁶, J. J. Jonsson^7,8;
¹Dept. of Genetics and Molecular Medicine, Landspitali, Reykjavik, Iceland, ²Dept. of Medical Oncology, Landspitali - The National University Hospital, Reykjavik, Iceland, ³Faculty of Health, Education and Society, Plymouth Univ., Plymouth, United Kingdom, ⁴Icelandic Cancer Registry, Reykjavik, Iceland, ⁵The Genetical Committee of the University of Iceland, Reykjavik, Iceland, ⁶West Midlands Regional Genetics Unit, Birmingham Women Hospital NHS Trust, Birmingham, United Kingdom, ⁷Landspitali - The National University Hospital, Reykjavik, Iceland, ⁸Department of Medicine, University of Iceland, Reykjavik, Iceland.

Poster Viewing with Authors (even poster numbers)

EPL5 EMPAG Plenary Session: Emerging issues in genetic counselling

EPL5.1 Self- and Other-Oriented Reassurance in Telegenetic Counselling
S. Sarangi¹, O. Zayts²;
¹Cardiff University, Cardiff, United Kingdom, ²The University of Hong Kong, Hong Kong, China.

EPL5.2 Profile of genetic counsellor and genetic nurse practice in Europe
H. Skirton¹, C. Cordier², D. Lambert³, U. Hosterey-Ugander⁴, M. Voelckel⁵;
¹Faculty of Health, Education and Society, Taunton, United Kingdom, ²University Hospital of Strasbourg, Strasbourg, France, ³Our Lady's Children's Hospital, Crumlin, Ireland, ⁴Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵La Timone Hospital, Marseille, France.

EPL5.3 Rational and reasonable: requests for genetic testing of children
I. Holme, G. Crawford, A. Fenwick, A. Lucassen;
Southampton University, Southampton, United Kingdom.

EPL5.4 Assessing the effects of genetic counseling for people with serious mental illness: findings of the first randomized controlled trial
J. Austin¹, C. Hippman¹, A. Inglis¹, A. Ringrose¹, J. Cheek², W. Honer¹;
¹University of British Columbia, Vancouver, BC, Canada, ²Vancouver Island Health Authority, Victoria, BC, Canada.

EPL5.5 Assessing wellbeing in women caring for children with Duchenne or Becker muscular dystrophy
H. L. Peay^1,2, K. Kinnett^1,3, B. Meiser⁴, A. Tibben²;
¹Parent Project Muscular Dystrophy, Richmond, VA, United States, ²Leiden University Medical Center, Leiden, Netherlands, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, ⁴Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

EPL5.6 Interventions and Outcomes for Inherited Retinal Dystrophy: A Qualitative Examination
R. Combs¹, G. Hall², M. McAllister³, K. Payne¹, S. Downes⁴, J. Lowndes⁴, A. Moore⁵, S. Devery⁵, G. Wright⁵, S. Ramsden², G. Black¹;
¹University of Manchester, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Cardiff University, Cardiff, United Kingdom, ⁴Oxford Eye Hospital, Oxford, United Kingdom, ⁵Moorfields Eye Hospital, London, United Kingdom.

Workshop WS13: Dilemmas in HD practice (joint Workshop with ESHG) (Tara Clancy, Rhona Macleod, Aad Tibben)

Concurrent Symposium S16. Debate on Informed Consent in New Technologies (joint Symposium with ESHG)

S16.1 How to inform individuals of the relevance of incidental WGA findings?, Christian Netzer, Germany

S16.2 Biobanks: should individuals be informed of findings from biobank studies? Can informed consent be realized?, Anne Cambon-Thomsen, France

S16.3 Informed consent in non-invasive prenatal diagnosis, Zuzana Deans, United Kingdom

Tuesday, June 26, 2012

EPL6 - EMPAG Plenary Session: Communicating genetic information

EPL6.1 Providing written information as an aid in Genetic Counseling - dispensable or helpful?
C. Walter^1,2, H. Berth³, F. Kreuz³, K. Schenck-Kaiser⁴, H. Schindelhauer-Deutscher¹;
¹Association Psychosocial Aspects of Human Genetics, Homburg/Saar, Germany, ²Institute of Human Genetics, Freiburg, Germany, ³Association Psychosocial Aspects of Human Genetics, Dresden, Germany, ⁴Association Psychosocial Aspects of Human Genetics, Freiburg, Germany.

EPL6.2 Communicating familial breast cancer risks: risk presentation formats and women's preferences
L. Henneman^1,2, C. J. Van Asperen³, J. C. Oosterwijk⁴, F. H. Menko¹, L. Claassen^1,2, C. F. Ockhuysen-Vermey^1,2, D. R. M. Timmermans^1,2;
¹VU University Medical Center, Amsterdam, Netherlands, ²EMGO Institute for Health and Care Research, Amsterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴University Medical Center, Groningen University, Groningen, Netherlands.

EPL6.3 The Signal-Trial: Evaluation of a Checklist to Improve Communication about Psychosocial Problems in Cancer Genetics
W. Eijzenga¹, N. K. A. Aaronson¹, D. E. E. Hahn¹, I. Kluijt¹, G. N. Sidharta¹, M. G. E. M. Ausems², E. M. A. Bleiker¹;
¹The Netherlands Cancer Institute, Amsterdam, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands.

EPL6.4 Disclosure of information within french families with BRCA mutation
C. Rambaud¹, A. Birot¹, A. Damette², C. Populaire², A. Cueff³, F. Coron¹, C. Loustalot⁴, C. Cassini¹, P. Fumoleau³, J. Sautière⁵, X. Pivot⁶, F. Debomy¹, S. Gauthier¹, M. Collonge-Rame², L. Faivre¹;
¹Centre de génétique, Hopital d'Enfants, Dijon, France, ²Service d'oncogénétique, Besançon, France, ³Service d'oncologie, Centre G.F. Leclerc, Dijon, France, ⁴Service d'oncogénétique, Centre G.F. Leclerc, Dijon, France, ⁵Service de gynécologie, Besançon, France, ⁶Service d'oncologie, Hôpital Minjoz, Besançon, France.

EPL6.5 The impact on self and family of receiving genetic test results following participation in the Australian Ovarian Cancer Study (AOCS)
N. Hallowell¹, K. Alsop², M. Gleeson³, D. Bowtell², G. Mitchell², .. The Australian Ovarian Cancer Study Group⁴;
¹PHG Foundation, Cambridge, United Kingdom, ²Peter MacCallum Cancer Centre, Melbourne, Australia, ³Hunter Genetics, Newcastle NSW, Australia, ⁴Westmead Institute for Cancer Research, University of Sydney and Millennium Institute, and Departments of Gynaecological Oncology, Westmead Hospital, NSW, Queensland Institute for Medical Research,, Australia.

EPL6.6 Enhancing family communication about genetics: ethical and professional challenges
C. Gaff^1,2, J. Hodgson^3,4;
¹Department of Medicine, The University of Melbourne, Melbourne, Australia, ²Victorian Comprehensive Cancer Centre, Melbourne, Australia, ³Murdoch Childrens Research Institute, Melbourne, Australia, ⁴Department of Paediatrics, The University of Melbourne, Melbourne, Australia.

11:00 - 12:30

EPL7 - EMPAG Closing Plenary Session

EPL7.1 Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeqTM study
B. B. Biesecker¹, F. M. Facio¹, H. Eidem¹, T. Fisher¹, S. Brooks¹, A. Linn¹, K. A. Kaphingst², L. G. Biesecker¹;
¹National Human Genome Research Institute, Bethesda, MD, United States, ²Washington University, St. Louis, MO, United States.

EPL7.2 Introducing high-throughput seqencing in the clinical setting - but what will patients think ?
A. Soulier, S. Leonard, S. Julia, A. Cambon-Thomsen;
UMR 1027, Inserm, Université de Toulouse - Université Paul Sabatier -Toulouse III, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps, Toulouse, France.

EPL7.3 Rapid genetic testing for BRCA1/2 genes: How could oncogenetic counseling deal with an urgent choice?
E. Razzaboni¹, L. Cortesi¹, G. Tazzioli², M. Pignatti³, A. Baccarani³, A. Andreotti², E. De Matteis¹, V. Medici¹, M. Federico¹;
¹Department of Oncology, Haematology and Respiratory Disease, Modena, Italy, ²Department of General Surgery and Surgical Specialities, Modena, Italy, ³Department of Plastic and Reconstructive Surgery, Modena, Italy.

EPL7.4 The impact of diagnostic developments in prenatal diagnosis; a psychological challenge
S. Riedijk, G. Oudesluijs, J. Hunfeld, S. le Sage, R. Galjaard, A. Tibben;
Erasmus Medical Center, Rotterdam, Netherlands.

EPL7.5 Close parental relatedness identified by SNP microarray - challenges for genetic counselling
R. Forbes¹, T. Burgess², D. Amor^1,3,4, Z. Stark¹;
¹Victorian Clinical Genetics Service, Royal Children's Hospital, Melbourne, Victoria, Australia, ²Victorian Clinical Genetics Service Pathology, Cytogenetics,Royal Children's Hospital, Melbourne, Victoria, Australia, ³Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia, ⁴University of Melbourne, Department of Paediatrics, Melbourne, Victoria, Australia.

EPL7.6 Criteria for responsible introduction of genome-based-technologies and information into public health care
H. C. Howard¹, E. Swinnen², K. Douw³, H. Vondeling³, J. Cassiman², A. Cambon-Thomsen⁴, P. Borry²;
¹University of Basel, Basel, Switzerland, ²KULeuven, Leuven, Belgium, ³University of Twente, Enschede, Netherlands, ⁴INSERM, Université de Toulouse 3 Paul Sabatier, Toulouse, France.

Awards & Closing remarks